AbbVie Aktie News

President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon."  But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.

I see a 50-60% chance of a recession in the next 12–24 months, so portfolio preparation is essential. I recommend the iShares Gold Trust Micro as a low-cost gold ETF that has outperformed during recent uncertainty and can hedge against downturns. I also like the iShares Core Dividend Growth ETF for its quality holdings, solid dividend growth, and resilience in volatile markets.

Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.

In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.18%). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes.

There's a strong parallel between investing for passive income and planting an apple tree. Both require some work up front.

AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases and gaining access to a new type of RNA delivery system. The acquisition will give the pharma giant control of CPTX2309, a lipid nanoparticle-based therapy that delivers mRNA directly into the body to progr...

AbbVie said on Monday it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion, adding experimental treatments for autoimmune diseases to its portfolio.